Testing a pill for large inflamed liver growths
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a daily pill (baricitinib) to shrink large, inflamed liver growths called inflammatory hepatocellular adenomas. It may be an option for people who have at least one growth larger than 5 cm and who are not using estrogen-containing birth control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a specific type of non-cancerous liver growth called an 'inflammatory hepatocellular adenoma' (confirmed by a biopsy).
- At least one of these growths is larger than 5 cm (about the size of a lime).
- You are not currently using birth control that contains estrogen (like some pills or patches).
- You are not pregnant or breastfeeding.
- You are between 18 and 65 years old.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of liver-directed chemotherapy (HAIC), an immunotherapy drug (sintilimab), and a drug that blocks blood vessel growth (bevacizumab biosimilar) for advanced liver cancer that hasn't been treated with systemic therapy before. The goal is to see if this triple therapy can shrink or control the cancer.
This study tests if baricitinib, an anti-inflammatory pill, can help people with arthritis caused by CPPD crystals (also called pseudogout). It is for people aged 55 and older who have swelling in their hands/wrists or large joints.
This trial tests baricitinib, an oral medication, for people with intestinal Behçet's disease that hasn't improved with standard treatments. It aims to see if baricitinib can reduce symptoms and help heal gut ulcers.
This trial tests a combination of immunotherapy (camrelizumab), a targeted drug (rivoceranib), and liver-directed chemotherapy (HAIC) to shrink liver tumors enough to make them removable with surgery. It is for people with intermediate or advanced liver cancer that has not spread outside the liver.
This trial tests if adding a combination of immunotherapy (adebrelimab), a targeted drug (apatinib), and chemotherapy into the liver artery (HAIC) before and after surgery can help people with resectable intrahepatic cholangiocarcinoma (a type of bile duct cancer). The goal is to see if this approach improves outcomes.
This trial tests a combination of three treatments for a rare form of liver cancer that is both hepatocellular and cholangiocarcinoma: HAIC (chemotherapy given directly into the liver artery), Camrelizumab (an immunotherapy that helps your immune system attack cancer cells), and Rivoceranib (a targeted therapy that blocks blood vessel growth to tumors). It may be an option if you haven't had prior systemic therapy for this cancer and your liver function is stable.
Hear when a new Inflammatory Hepatocellular Adenoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.